The Lab

What Medicare's GLP-1 Coverage Means for Your Research Vials
What Medicare's GLP-1 Coverage Means for Your Research Vials

The recent expansion of Medicare coverage for GLP-1 receptor agonists marks a significant shift in the accessibility of these compounds, not just for patients, but for the research community that... Read more...
Why Your Peptide Loses Potency After Reconstitution
Why Your Peptide Loses Potency After Reconstitution

The push to make peptide therapies more readily available isn't just about scaling manufacturing or cutting costs. It's about addressing a fundamental problem that anyone who's ever reconstituted a peptide... Read more...
Why enzyme-made peptides are changing what you buy and how you store them
Why enzyme-made peptides are changing what you buy and how you store them

If you've been buying peptides for any length of time, you've noticed the shift. The vials look the same. The labels read the same. But something under the hood has... Read more...
Why BPC-157 Stays Stable When Other Peptides Degrade
Why BPC-157 Stays Stable When Other Peptides Degrade

BPC-157 has been quietly occupying lab benches and animal research facilities for decades, yet it remains one of the most misunderstood peptides in the research community. The compound, a synthetic... Read more...
What GLP-1 Stability Means for Your Research Vials
What GLP-1 Stability Means for Your Research Vials

The Research Behind GLP-1 and Chemotherapy The news that GLP-1 receptor agonists are being investigated alongside chemotherapy represents a significant expansion of how these compounds are being studied in cancer... Read more...
The cold chain reality most GLP-1 researchers discover too late
The cold chain reality most GLP-1 researchers discover too late

GLP-1 receptor agonists have moved from obscure endocrinology papers to mainstream headlines, but the research community handling these compounds faces a quieter challenge: keeping them stable once they leave the... Read more...
Why GLP-1 Supply Crunch Matters Even If You're Just Doing Research
Why GLP-1 Supply Crunch Matters Even If You're Just Doing Research

You've probably seen the headlines by now: North Texas cities are cutting services because GLP-1 weight-loss drugs are eating up municipal budgets. Dallas-Fort Worth alone is staring at millions in... Read more...
Why employers are saying no to GLP-1 coverage, and what it means for your research
Why employers are saying no to GLP-1 coverage, and what it means for your research

If you've been trying to source GLP-1 receptor agonists for your lab recently, you may have noticed something odd: the compounds are everywhere in the news, but getting your institution... Read more...
Why your GLP-1 research samples might be losing potency
Why your GLP-1 research samples might be losing potency

GLP-1 (glucagon-like peptide-1) has become one of the most studied peptides in metabolic research over the past decade. As a 30-amino-acid hormone secreted by intestinal L-cells in response to food... Read more...
Why Your GLP-1 Research Samples Need Better Storage
Why Your GLP-1 Research Samples Need Better Storage

GLP-1 receptor agonists have moved from obscure endocrinology papers to mainstream headlines, but the underlying peptide chemistry hasn't changed. If you're working with GLP-1 analogs in a research setting, whether... Read more...
Why your reconstituted GLP-1 compounds degrade faster than expected
Why your reconstituted GLP-1 compounds degrade faster than expected

GLP-1 receptor agonists have moved from niche diabetes research to mainstream pharmaceutical headlines, with prescription data showing millions of Americans now using these compounds. For researchers working with GLP-1 analogs... Read more...
Why breakthrough peptide news quietly wrecks researcher vials
Why breakthrough peptide news quietly wrecks researcher vials

When a peptide hits clinical trial news, the research community pays attention. A recent breakthrough showing nerve repair potential after spinal cord injury is the kind of development that shifts... Read more...
Why your reconstituted peptide might be weaker than the label says
Why your reconstituted peptide might be weaker than the label says

The GLP-1 drug surge isn't just a pharmaceutical story, it's hitting peptide research labs right now. Whether you're scaling up FOXO4-DRI work, running KPV cycles, or just keeping melanotan stable,... Read more...